Clients News • MC Services corporate website
5522
paged,page-template-default,page,page-id-5522,paged-36,page-paged-36,bridge-core-2.1.4,qode-listing-1.0.1,qode-social-login-1.0,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,paspartu_enabled,qode_grid_1400,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-20.1,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-6.1,vc_responsive

CLIENT NEWS

 

 

  • Heidelberg Pharma to present its proprietary ATAC technology platform at the AACR Annual Meeting 2019
    www.heidelberg-pharma.com
  • Breath Therapeutics Announces Initiation of Global Phase 3 Trials for the Treatment of Bronchiolitis Obliterans Syndrome
    www.breath-therapeutics.com
  • Motif Bio plc: Proposed Equity Fundraise
    www.motifbio.com
  • Adrenomed’s Adrecizumab successfully passes interim analysis in early septic shock study AdrenOSS-II
    www.andrenomed.com
  • MagForce AG successfully completes installation of mobile NanoTherm treatment center for brain tumors in Poland
    www.magforce.de
  • Breath Therapeutics Announces Presentations at Upcoming Scientific Conferences
    www.breath-therapeutics.com
  • Topas Therapeutics to Participate at Upcoming Industry and Scientific Conferences
    www.topas-therapeutics.com
  • Motif Bio Granted Meeting with U.S. FDA regarding Iclaprim
    www.motifbio.com
  • Probiodrug and Alzheimer’s Disease Cooperative Study (ADCS) Receive 15 Million USD National Institutes of Health (NIH) Grant for U.S. Phase 2b Core Program for PQ912
    www.probiodrug.de
  • MorphoSys and I-Mab Biopharma Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma
    www.morphosys.com